Is the third generation lung cancer targeted drug osimertinib effective?

The third generation lung cancer targeted drug osimertinib has shown remarkable results in the treatment of non-small cell lung cancer (NSCLC). Osimertinib is a targeted drug that targets epidermal growth factor receptor (EGFR) mutations. It is mainly used to treat patients with non-small cell lung cancer who carry EGFR sensitive mutations or T790M resistant mutations. By specifically inhibiting these mutated EGFRs, osimertinib can block the growth, proliferation and metastasis of tumor cells, thereby achieving the purpose of treating tumors.

In terms of clinical application, osimertinib has achieved remarkable results. First, it significantly improved patients’ median progression-free survival (PFS) and median overall survival (OS). In the Phase III clinical trial of osimertinib, patients had a median PFS of 18.9 months Months, the median OS lasted 38.6 months, both of which hit record highs [2]. This means that patients can have their disease under stable control for a long time after using osimertinib, thereby improving their quality of life and prolonging their survival.

Osimertinib has also shown good efficacy in patients with brain metastases. Brain metastasis is a common complication in non-small cell lung cancer, and osimertinib can penetrate the blood-brain barrier, provide good control of brain and meningeal lesions, and has a certain preventive effect. In clinical trials for patients with brain metastases, the intracranial objective response rate (ORR) of osimertinib was significantly better than that of chemotherapy, and the progression-free survival was also significantly prolonged.

Osimertinib also performed well in comparisons with other targeted drugs for lung cancer. In comparative trials with other generation targeted drugs, osimertinib has shown advantages in both efficacy and side effects. For example, compared with Iressa and Tarceva, osimertinib had a longer median PFS and reduced the risk of lung cancer progression by 54%. At the same time, osimertinib also has fewer side effects,3The incidence rate of adverse reactions above grade (serious side effects) is relatively low.